EAMA
NBIX icon

EFG Asset Management (Americas)’s Neurocrine Biosciences NBIX Stock Holding History

EFG Asset Management (Americas)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,774
Closed -$245K – 131
2024
Q1 		$245K Sell
1,774
-1,033
-37% -$141K 0.07% 120
2023
Q4 		$370K Sell
2,807
-410
-13% -$47.2K 0.08% 117
2023
Q3 		$362K Buy
3,217
+77
+2% +$8.11K 0.09% 117
2023
Q2 		$296K Buy
3,140
+469
+18% +$45.8K 0.07% 126
2023
Q1 		$270K Buy
2,671
+603
+29% +$62.7K 0.06% 124
2022
Q4 		$247K Sell
2,068
-124
-6% -$14.5K 0.06% 121
2022
Q3 		$233K Hold
2,192
– – 0.06% 127
2022
Q2 		$214K Sell
2,192
-130
-6% -$12K 0.05% 127
2022
Q1 		$218K Buy
+2,322
New +$197K 0.04% 132
2020
Q2 		– Sell
-20,240
Closed -$1.75M – 128
2020
Q1 		$1.75M Buy
20,240
+229
+1% +$22.4K 0.56% 63
2019
Q4 		$2.15M Sell
20,011
-4,440
-18% -$465K 0.57% 66
2019
Q3 		$2.2M Buy
+24,451
New +$2.28M 0.66% 61
2019
Q1 		– Sell
-22,184
Closed -$1.58M – 119
2018
Q4 		$1.58M Buy
22,184
+2,363
+12% +$226K 0.57% 65
2018
Q3 		$2.44M Buy
+19,821
New +$2.25M 0.7% 57

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

EFG Asset Management (Americas)'s NBIX Position: Q2 2024 in Review

EFG Asset Management (Americas) sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 1,774 shares — an estimated $245K sold.

EFG Asset Management (Americas) first reported a position in NBIX in Q3 2018 and held it in 14 quarters. The position peaked at $2.44M in Q3 2018. 594 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

  • EFG Asset Management (Americas) reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
  • EFG Asset Management (Americas) sold 1,774 Neurocrine Biosciences shares in Q2 2024, an estimated $245K.
  • EFG Asset Management (Americas) first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 14 quarters.
  • EFG Asset Management (Americas)'s Neurocrine Biosciences position peaked at $2.44M in Q3 2018.
  • 594 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on EFG Asset Management (Americas)'s 13F filing for Q2 2024, filed 6 Aug 2024.